Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. (October 2022)

• Record Type: Journal Article
• Authors: Tringale, Kathryn R.; Tyagi, Neelam; Marsha Reyngold, ; Romesser, Paul B.; Wu, Abraham; O'Reilly, Eileen M.; Varghese, Anna M.; Godoy Scripes, Paola; Khalil, Danny N.; Park, Wungki; Yu, Kenneth; Crane, Christopher H.
• Is Part Of: Physics and imaging in radiation oncology. Volume 24(2022)
• Page Start: 88
• Page End: 94
• Publication Date: 2022-10
• Subjects: Pancreas cancer -- MR linac -- MRI -- Ablative radiation therapy; Radiotherapy -- Periodicals; Radiation dosimetry -- Periodicals; Cancer -- Imaging -- Periodicals; Oncology -- Periodicals; 615.842
• DOI: 10.1016/j.phro.2022.10.003
• Languages: English
• ISSNs: 2405-6316

Abstract

Highlights: Ablative radiation therapy (A-RT) is effective for locally advanced pancreas cancer. 30 patients received A-RT using diagnostic quality MR-adaptive treatment delivery. Cumulative incidences of 1-year local and distant progression were 19.3% and 47.4% Overall and progression-free survival 1-year from A-RT was 80.0% and 39.7% 50 Gray in 5 fractions led to promising 1-year local control and survival. Most local failures were marginal at the tumor-organ-at-risk (OAR) interface. No grade 3 or higher toxicities were observed despite adjacent sensitive OARs. Abstract: Purpose: Ablative radiation therapy (A-RT) appears to improve outcomes in locally advanced pancreatic cancer (LAPC) yet requires solutions for respiratory and digestive motion. We report outcomes of A-RT for pancreatic cancer using 1.5 T MR-adaptive treatment delivery. Methods: Between March 2020 and July 2021, we treated 30 patients with pancreatic cancer with 50 Gy in 5 fractions (biologically effective dose [BED10] = 100 Gy10) using a novel compression belt workflow and remote planning on the Unity 1.5 T MR linac system. Cumulative incidence of progression was computed from A-RT initiation with death as a competing risk. Overall (OS) and progression-free survival (PFS) were calculated using Kaplan Meier methods. Results: Of 30 patients, most (73 %) were locally advanced, 4 (13 %) were metastatic, 2 (7 %) were medically inoperable, and 2 (7 %) were locally recurrent. Most (73 %) received FOLFIRINOX prior to A-RT. Median follow-up times from diagnosis and A-RT were 17.6 (IQR 15.8–23.1) and 11.5 months (IQR 9.7–16.1), respectively. Cumulative incidences at 1-year of local and distant progression were 19.3 % (95 %CI 6.7–36.8 %) and 47.4 % (95 %CI 26.7–65.6 %), respectively. Median OS from diagnosis and A-RT were not reached. One-year OS from diagnosis and A-RT were 96.4 % (95 %CI 77.2–99.5 %) and 80.0 % (95 %CI 57.3–91.4 %), respectively. Median and 1-year PFS were 10.1 months (95 %CI 4.4–14.4) and 39.7 % (95 %CI 20.3–58.5 %), respectively. No grade 3 + toxicities were observed. Conclusions: A-RT using the 1.5 T Unity MR Linac resulted in promising LC and OS with no severe toxicity in patients with LAPC despite radiosensitive organs adjacent to the target volumes. Longer follow-up is needed to assess long-term outcomes.